NCT04774250View on ClinicalTrials.gov

Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

December 23, 2022

Study Completion Date

December 23, 2022

Conditions
Hearing Loss, Noise-Induced
Interventions
DRUG

Zonisamide 100Mg Cap

ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.

DRUG

Placebo

The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.

Trial Locations (1)

44325-3001

University of Akron, Akron

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

University of Texas

OTHER

collaborator

Gateway Biotechnology, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER